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ABSTRACT
The scientific and clinical interest in extracellular vesicles (EV) has grown exponentially during the
past 15 years. As most research indicates that EVs can be utilised in diagnostics, prognostics and
therapeutics, we may be on the brink of establishing the clinical utility of EV measurement, but
how can we make this a reality? If we are to introduce EVs as biomarkers into clinical laboratories,
it will be necessary to offer fully validated, International Organization for Standardization (ISO)
standard 15189 assays. ISO 15189 defines the quality management system requirements parti-
cular to medical laboratories and is used internationally to determine accreditation. In order for
a clinical laboratory to offer an accredited test for EVs, this assay must have been subjected to
a thorough assay validation process. This process requires the generation of data related to
defined performance characteristics, to ensure that an assay is performing in accordance with the
needs of its clinical users. Each of the defined performance characteristics will be discussed in this
review, along with the issues that specifically affect EV analysis. Accreditation is increasingly
important for all clinical laboratories and the standards required to achieve this are becoming
more and more stringent. Therefore, as companies seek to develop the best assays to detect EVs
and their molecular contents for clinical utility, and as we move rapidly towards our goal of
offering EV analysis in the diagnosis and monitoring of disease, it is timely to highlight the
requirements for the clinical accreditation of such assays. It is essential to consider these para-
meters to ensure that we develop the highest quality assays possible and ultimately the best
outcomes for patients.
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Introduction
The scientific and clinical field of extracellular vesicles
(EVs) has been rapidly expanding over the past 15 years.
Publications focussing on exosomes and microvesicles
have grown exponentially since 2000 [1]. As some of the
first EV assays start to demonstrate a true clinical utility
and gain FDA and international approvals [2], the pro-
cess of introducing an assay into a clinical laboratory
needs to be considered.
We have moved on from the initial “Wild West” of EV
analysis, into a time where law and order starts to prevail,
and this is being established with the promotion of stan-
dardisation studies and initiatives, such as EV Transparent
Reporting and Centralising Knowledge (EV-TRACK) [3]
and Minimal Information for Studies of EVs (MISEV)
[4–6]. This review considers the next steps required as we
move towards clinical implementation of such assays. It is
noted that a wide range of techniques are currently avail-
able of EV analysis. These are listed in Table 1 along with
their advantages and limitations in relation to their use
clinical. Several recent reviews have discussed these tech-
niques in more detail [7–12].
The introduction of a new assay into a clinical labora-
tory requires several steps, which are laid out in Figure 1.
The first step is the establishment of a clinical need, which
is driven by the current literature and identification of
gaps in the current diagnostic pathway being utilised.
Suitable commercial or in-house assays are then identi-
fied and compared with existing diagnostic protocols, for
example the current gold standard test for a disease. If the
new assay demonstrates an advantage to the existing test,
the assay will be subjected to further scrutiny prior to
introduction, by either a Validation or Verification pro-
cess (defined in Table 2).
For in house methods, the laboratory will assess the
performance characteristics to ensure that the assay per-
forms at an adequate level within that clinical labora-
tory, a process known as Validation. For commercial
assays, these performance characteristics should have
been analysed by the company and published within
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the instruction manual. The clinical laboratory will then
undertake confirmatory testing to ensure that the stated
characteristics of the assay are reproducible within the
clinical setting, a process known as Verification.
This review will focus on the steps of the Validation/
Verification procedure and how all these steps relate spe-
cifically to EV analysis. However, it is important to note
that other factors such as availability of equipment, main-
tenance, training of staff, information technology systems
and clinical reporting all need to be considered in order for
the clinical assay to be implemented. In addition, any new
assay will be subjected to a continuous improvement pro-
cess, via regular batch acceptance and audits of perfor-
mance, to ensure that the test continues to perform at the
highest level possible.
In order to fully validate an assay for clinical use and
International Organization for Standardization (ISO) stan-
dard 15189 [13], which has been widely internationally
accepted as the mandatory regulatory standard for clinical
laboratories, it is essential to determine performance char-
acteristics, including trueness, precision, clinical sensitivity
and specificity, linearity, analytical sensitivity, analytical
Table 1. Technique comparison of clinical EV analysis.
Technique Advantages Limitations References
Conventional Flow Cytometry Widely available in clinical laboratories
Clinical validated machines
Possible to phenotype
High throughput and automation
Good reproducibility
Limited sensitivity
Variability known to occur between different machines
Requires expertise
[31,56]
High Sensitivity Flow Cytometry Good resolution
Possible to phenotype
High throughput
Good reproducibility
Expensive
Requires expertise
[10,42,57,58]
Nanoparticle Tracking Analysis High resolution
Possible to phenotype
Good reproducibility
Throughput
Specificity – Designed for monodisperse populations
[10,18,59–62]
Dynamic Light Scattering High resolution
Good reproducibility
Throughput
Specificity – Designed for monodisperse populations
[60,62–64]
Resistive Pulse Sensing High resolution
Good reproducibility
Throughput
Specificity – Designed for monodisperse populations
[10,62,65]
Electron Microscopy High resolution
Possible to phenotype
Not widely available
Expensive
Throughput
Poor Reproducibility
[11]
Figure 1. Introduction of clinical assays.
Table 2. Definitions of terms.
Term Definition
Clinical Assay Any test being used to generate results that will
be used diagnostically and may influence
clinical decisions about a patient.
Clinical Laboratory
Accreditation
A process to ensure the quality of results
generated meet ISO 15189 standards
User Required
Specifications (URS)
The required performance of a clinical assay, as
defined by the clinical users either within an
institution or nationally/internationally by
a consensus publication
Validation Analysis of performance characteristics to ensure
that the assay meets the URS
Verification Confirmation of performance characteristics of
a commercial kit to ensure that the assay
meets the URS
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specificity, sample stability and diversity, and uncertainty
of measurement (UoM) (defined in Table 3). These per-
formance characteristics are compared to User Required
Specification (URS), which are defined by the clinical users
of the assay either within an institution or nationally/inter-
nationally by a consensus publication, and vary depending
on that assays utility. Each of the performance character-
istics are reviewed below alongwith specific issues affecting
EV analysis.
Assay performance characteristics
Although EVs occur in all body fluids, this reviewwill focus
on EVs in blood. Previous studies have found that EV
measurement in plasma is sensitive to pre-analytical vari-
ables, such as phlebotomy technique, anticoagulant, sample
transport and agitation, temperature, processing and sto-
rage [12,14–23]. In addition, analytical variables, such as
the sensitivity of the flow cytometer used for detection,
greatly impact on EV levels detected [22,24,25].
Therefore, differences in techniques need to be clearly
defined to ensure that the levels of EVs reported can be
reliably interpreted.
Trueness
Trueness is defined as a qualitative assessment of the
closeness of the measured value to the true or con-
ventionally true value. Trueness is essentially the same
as the older and outdated term “accuracy”. Ideally
trueness would be determined against an
International Reference Preparation (IRP), which
forms the basis for uniform reporting of results.
Initially, it may appear difficult to verify the trueness
of EVs, as there is currently no IRP available for EV
measurement. However, this is also the case for many
other clinical analytes [26]. Therefore, alternative stra-
tegies have been devised to determine the trueness of
such analytes, including establishing an external qual-
ity assurance scheme [13].
This scheme would require a reference laboratory to
produce a reference sample, which would be distributed
to all participating laboratories. Such a process is cur-
rently being set-up by the Hendrix lab at University of
Ghent [27]. The reference sample needs be homoge-
nous, monodisperse, stable, safe (non-infectious), of suf-
ficient volume to supply all participants and of a similar
matrix to the samples being tested, i.e. plasma with EVs
spiked in. The target values for each sample can be
determined by an expert panel or by consensus of all
participants. For this to be successful, we would need to
establish the effects of storage and transportation on EV
levels to ensure optimal reproducible conditions.
The participating laboratories will test the sample
and return their results including details on the storage
of the sample prior to analysis and the analysis plat-
form used. The reference laboratory will then compile
and analyse this data, generate a performance score for
the laboratory based on the reported value versus the
target value. If multiple platforms are used then this
data can be displayed separately for different machines,
to indicate any bias in a particular platform. The true-
ness of the EV measurement of any given techniques
can then be determined using performance from the
external quality assurance data.
Several studies have shown that different platforms, and
even the same platforms in different laboratories, will give
significantly different results for the same sample [28–30].
Differences in calibration and maintenance of equipment
and training of operators may at least in part contribute to
this. One way to reduce differences between laboratories
and instruments would be to produce a universally agreed
standardisation protocol. An inter-laboratory standardisa-
tion study has recently been conducted by van der Pol et al.,
which evaluated flow cytometry EV gating across 46 flow
cytometers using software to correct for differences in
refractive index and the optical set-up of the flow cyt-
ometers used [31].
External quality assurance schemes should strive to
provide education to participants and to companies produ-
cing clinical assays in order to improve their performance,
through commentaries, presentations and training days.
Therefore, the commitment to become a reference labora-
tory for EV analysis would be a large undertaking and
ideally would be shared between several expert groups in
the field. Early collaborations are developing in specific
areas of EV research, such as the Extracellular RNA
Communication Consortium (ERCC) supported by
National Institute of Health’s The Common Fund, who
Table 3. Performance characteristics for assay validation.
Performance
characteristic Definition
Trueness Qualitative assessment of the closeness of the
measured value to the true value
Precision Measurement of how close a group of
measurements are to each another
Clinical Sensitivity Ability to identify all individuals with a condition
Clinical Specificity Ability to identify all individuals without
a condition
Linearity Ability to detect an analyte in a linear fashion
across the reportable range
Analytical
Sensitivity
Lowest level that can be reliably detected
Analytical
Specificity
Effect of interfering substances on the assay
Sample Stability Acceptable conditions and time that a sample can
be stored prior to analysis
Sample Diversity Range of sample types that can be used on the
assay
Uncertainty of
Measurement
Range of the values that could reasonably be
attributed to the measured quantity
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are focusing on the RNA extraction including standardised
protocols (exrna.org).
Precision
Precision is a measurement of how close a group of
measurements are to each another. It is reported as
a Coefficient of Variation (CV%), with lower CV%
indicating that the data replicates are close to one
another. Thus, precision gives a measurement of con-
fidence that an analyte measured once will give the
same result if measured again.
For each assay it is essential to establish its precision
and the level of imprecision should be acceptable for the
URS. The acceptable levels of precision will vary depen-
dent on techniques and the differences detected between
patient groups. For example, a relatively high CV% may
be acceptable if the difference in levels between patients
and controls is large or binary, but if the difference is
small the CV% needs to be much tighter.
Different techniques also generate different precision
levels, for example flow cytometry produces greater
imprecision than chemical analytes measured on auto-
mated machines, due to subjectivity and variability
between operators [32]. Several methods have been uti-
lised for EV analysis in blood, including flow cytometry,
dynamic light scattering, nanoparticle tracking analysis
(NTA), electron microscopy, atomic force microscopy,
tunable resistance pulse sensing, fluorescence correlation
spectroscopy and ELISA-based methods. Each of these
methods have advantages and disadvantages, as
reviewed previously [33,34], and each method is likely
to have different levels of precision.
When establishing precision, it is necessary to define
the intra-assay, inter-assay, inter-user and inter-batch to
determine the likely variability when used in a clinical
setting. This requires a panel of samples with varying
levels of EVs to be run multiple times within one assay,
across several different assays, performed by different
scientists and over several lot numbers of a kit. In
practice, the intra-assay, inter-assay and inter-user pre-
cision should be established before using the assay clini-
cally, however establishing the inter-batch variability is
usually carried out prospectively as this can take several
months or even years.
In addition, clinical laboratories are required to
batch test all new batches of diagnostics kits and
there are limits of acceptability. If batches vary signifi-
cantly from previous results, the kits may be rejected,
wasting time and resources. Therefore, companies need
to consider how reproducible their assays are between
batches to prevent unnecessary wastage of products
and to ensure a better clinical performance of the assay.
Clinical sensitivity and specificity
The definition of clinical sensitivity and clinical speci-
ficity are often confused. One way to define them is to
consider the following two questions:
(1) Clinical Sensitivity – Can the EV assay identify all
patients with a condition (a test with poor clinical
sensitivity may result in higher numbers of false
negatives).
(2) Clinical Specificity – Can the EV assay identify all
individuals without disease (a test with poor clin-
ical specificity may result in higher numbers of
false positives).
In reality no clinical assays have 100% sensitivity and 100%
specificity, and this is also very unlikely to be the case for
EV-based assays. So it is important to optimise the cut-off
for a clinical assay to achieve the best clinical sensitivity and
clinical specificity, using Receiver Operating Curves
(ROC). The area under the ROC curve can also be used
to determine the overall performance of a test, a value of 1
indicating a perfect test and a value of 0.5 suggesting that
the test has no clinical utility.
The trade-off between sensitivity and specificity will
vary depending on intended clinical use of the assay,
i.e. screening or diagnostic. Screening tests should have
a high sensitivity, but may be less specific, whereas
diagnostic tests need to be highly specific.
The definition of normal versus abnormal for EVs
and hence where to place a clinical cut off may be
clouded by the large spread in reported concentration
of EVs detected in plasma of healthy humans [35–37].
However, in order for meaningful clinical analysis of
EVs, it is essential to establish a “normal reference
range”. The generation of the data to define reference
ranges and thus to define cut-offs requires large num-
bers of samples that have been stringently processed.
As previously stated there is great variability between
analysis of EVs in different laboratories [10], including
differences in EV extraction and analysis, making it
impossible to combine this data from different studies.
Therefore, we need standardisation of protocols across
laboratories, before we can consider pooling data. This
is an important area of validation that EV-specific
Biobanks may be able to support, by providing well-
defined samples from healthy individuals for assay
development.
Although clinical sensitivity and specificity are sta-
ted as required ISO 15189 performance characteristics,
in reality clinicians are often more concerned with
a test’s Positive Predictive Value (PPV) and Negative
Predictive Value (NPV). They can be calculated from
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the same data as clinical sensitivity and specificity and
are defined as:
(1) PPV – Percentage of people with a positive result
who actually have the condition
(2) NPV – Percentage of people with a negative result
who do not have the condition
Therefore, when stating the clinical sensitivity and spe-
cificity for an assay with a defined reference range, it is
useful to also provide the PPV and NPV to aid clinical
utility of the assay.
Linearity
Linearity is the ability of a clinical assay to detect an
analyte in a linear fashion throughout its reportable
range and it is established by serially diluted samples
with high concentrations of EVs. There is likely to be
great variability in circulating EV levels between indi-
viduals, so clinical assays should be able to measure
EVs over a wide range and be able to do this linearly,
still a known issue in the field [10,34]. Linearity mea-
surement can also be used to assist in the determina-
tion of the assays lower limit of detection, which must
be clearly stated in the kit specifications.
Assays that utilise antibodies suffer from antigen-
excess effects, particularly for analytes which have a very
wide range of levels [30]. In addition to antigen-excess,
EV analysis by flow cytometry faces the challenge of
swarm detection. Standard flow cytometers are optimised
to detect cells as an individual event, which are much
larger than EVs. Therefore, depending on the flow cyt-
ometer set-up and flow rate, multiple vesicles can be
detected as a single event [38,39]. Swarm detection can
be identified by serial dilution of samples to check for
linearity [40], and in plasma samples with particular high
concentrations of EVs, it may be necessary to implement
dilution factors in order to limit the impacts of swarm
detection. Linearity experiments using NTA and tunable
resistive pulse sensing (TRPS) of plasma EVs show
a reasonable linearity in the range of 1.0–10.0 × 108 par-
ticles/mL for NTA and 1.0 × 108–1.8 × 109 particles/mL
for TRPS [41], suggesting that these two methods are not
affected by swarm detection.
Analytical sensitivity (lower limit of detection)
The analytical sensitivity for any clinical assay should
be determined by the manufacturer and subsequently
checked by the users. The lowest limit of detection
will be the lowest concentration at which the assay
can reproducibly report a result. This value can be
determined by measuring the precision in samples
with a known low concentration. The precision of
the assay in these low samples should still meet the
URS stated for the assay, to demonstrate consistent
reproducibility of the assay at its limit of detection.
Once the concentration reaches a point that the pre-
cision CV% is greater than the URS, then the sample
is below the analytical sensitivity of the assay.
Therefore, samples at this value and below should
be reported as less than the limit of detection.
For EVs the analytical sensitivity could also refer to
for example the smallest diameter of a vesicle that the
assay can detect. It is important to note that the size
distribution of EVs is log normal, meaning that there
are many more small vesicles than large vesicles.
Therefore, a small increase in the size sensitivity of an
assay will result in a great increase in the number of
vesicles it can detect. This has been demonstrated by
high-sensitivity versus standard flow cytometry, and
across other methods including NTA and resistive
pulse sensing, where the increase in the resolution of
the machine to detect smaller vesicles has led to an
exponential increase in the numbers of vesicles
detected [25,31,42,43].
Analytical specificity (interference)
Interference covers any other factors within a sample
that affect the result other than the intended analyte.
For EVs we are already aware of several such factors. It
was noted that consumption of a high fat meal lead to
a significant elevation of endothelial microvesicles in
the circulation [44–46], although the impact of circu-
lating chylomicrons may interfere with analysis.
Does this mean that EV analysis needs to be per-
formed on fasting blood samples? Other analytes also
require fasting bloods, such as lipid profiles and blood
sugars. However, compliance is not high and it is not
always possible, particularly if the patient presents to
an emergency clinic, so there is a move to reduce the
need for fasting samples [47]. The requirement for
fasting samples may well be dependent on the nature
and methodology of the assay, as some techniques may
be more prone to detecting interfering lipids.
Another interfering factor is haemolysis, which is
a common problem in clinic-obtained samples. By the
very nature of haemolysis it will artificially induce EVs
from RBCs, altering the quantification of EVs and
potentially affecting the miRNA content [48]. So how
do we control for haemolysis? Good phlebotomy pro-
cedures and protocols are essential, but in a clinical
setting these may not always be adhered to, due to staff
and time constraints. Therefore, laboratories will need
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to assess samples for evidence of haemolysis. A visual
inspection of samples for haemolysis is insufficient and
measurement of haemolysis can be done by spectro-
photometry. Ultimately an assay that is not signifi-
cantly affected by haemolysis or one that provides
quality controls on samples that are haemolysed should
be the aim.
The interfering factor in EV analysis that has
troubled researchers for many years is platelets. No
processing and centrifugation protocol can effectively
remove all platelets whilst retaining all EVs, and to our
knowledge, no assays have been described that suffi-
ciently distinguish small platelets from large (platelet
derived) EVs. Platelet-depleted-plasma is potentially
the best samples we can hope to achieve. The freezing
of this plasma can result in the post venepuncture gen-
eration of platelet-derived EVs and a skewing of the
miRNA profile. It is essential that this is acknowledged
within EV assay development, so the sample require-
ments for the assay are stringently defined whilst still
being pragmatic for clinical practice. One suggestion
would be to measure the platelet or RBC contamination
in samples prior to storage.
Sample stability
Sample stability refers to how long and under which
conditions a sample can be stored prior to analysis,
without significantly impacting the results. It has been
a key consideration of EV measurement in biological
fluids for many years, whether it be the question of how
quickly blood samples need to be centrifuged to produce
platelet poor plasma [16–18,20], to how long urine
samples can be stored in the fridge [49]. Stability data
of EVs is an area where a reasonable literature base
exists, although it should be noted that most of this
literature was derived prior to the recommendation of
standardisation protocols [47]. Therefore, novel stability
data should be generated once standardisation protocols
have been implemented.
The testing of sample stability should be applied to
any clinical EV assay to determine the maximum time
limits for sample storage. This is an essential perfor-
mance characteristic for clinical samples, which often
need to be taken in busy clinics and transported to
laboratories prior to processing. EV assays will need
to be robust enough to withstand such transport and
logistical limitations. Several studies have suggested
that miRNAs either free or within EVs are remarkably
stable when isolated from both plasma and urine
[50,51], suggesting that miRNAs may be a more
robust and pragmatic biomarker of disease, than EVs
themselves.
The stability of stored samples should also be con-
sidered. Many clinical laboratories will store samples
prior to sample analysis. At what temperature and for
how long can these samples be stored? Many EV assays
for quantification, phenotyping and contents analysis
have been shown to be relatively stable in samples
stored at −80°C, but often clinical laboratories will
not have the facilities to store large numbers of samples
at this temperature. Therefore, the aim should be to
generate assays that can be used for samples that have
been stored under conditions that are widely available.
Sample diversity
Sample diversity refers to the range of acceptable sam-
ple types that can be used for the assay. Traditionally,
for the measurement of circulating EVs, most protocols
have advocated the use of tri-sodium citrate tubes.
However, several recent studies have suggested that
samples taken in EDTA tubes may provide better sam-
ple stability for the measurement of platelet and ery-
throcyte microvesicles [14,15], and therefore EDTA
samples may be more applicable to a clinical setting.
In addition, at the ISEV 2018 meeting, many clinical
groups were using EDTA blood samples, potentially as
these are more widely used stored for clinical studies.
Other groups recommend the use of acid citrate dex-
trose (ACD) samples for EV analysis [52]. However,
currently there is limited comparison data between the
different coagulant blood tubes. In addition, appropri-
ate anti-coagulants for downstream processing, such as
miRNA analysis, should be considered. This area
requires further investigation to determine the most
appropriate samples, but could open up the potential
of utilising samples that have already in stored, for
example in clinical Biobanks.
Uncertainty of measurement
UoM is a parameter, associated with the result of
a measurement (e.g. an assay) that defines the range
of the values that could reasonably be attributed to the
measured quantity [13]. UoM may well be the most
important characteristic defined during assay valida-
tion. It gives a coefficient of variance which takes into
account all sources of variation associated with the pre-
analytical, analytical and post analytical variables. This
measurement can be stated alongside a patients result
in order to inform a clinician of the range of values in
which that sample is likely to fall. This can impact
decisions regarding diagnosis, prognosis and treat-
ments. For certain clinical biochemical analyses the
UoM may be very tight, and this is essential for
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analyses that even small changes have serious implica-
tions. For other functional assays, the UoM may be
large and this needs to be clearly stated on results.
UoM is often considered to be the most difficult
performance characteristic to calculate and is therefore
often avoided. However, as stated above this value is
often the most clinically relevant statistic to quote and
therefore it should be addressed. It is also true that the
statistics used to generate the UoM value are less applic-
able to qualitative than quantitative assays, but it can still
be done [53].
For EVs there are some special considerations. We
are already aware of many pre-analytical variables that
may influence EV measurement, several of which are
mentioned above. The UoM can be used to offset some
of these concerns regarding pre-analytical variables, as
it gives the opportunity to acknowledge and quantify
their impact and to appropriately caveat clinical results.
Different diseases are likely to alter different subsets
of EVs, due to differing cells becoming activated or
dying; therefore, the measurement of multiple EV sub-
types may be clinically useful. The UoM will be differ-
ent depending on the sub-type of EVs being
determined, with platelet-derived MVs likely to have
the greatest UoM, due to the inherent problem with
platelet contamination in plasma samples.
Discussion
The above performance characteristics have highlighted
some major hurdles when it comes to the clinical appli-
cation of EV diagnostics. The issues have been high-
lighted in Table 4 along with some of the potential
solutions we may use to address them.
The lack of a defined IRP creates several difficulties in
assay development. However, as has been highlighted
here, there are several schemes being set-up by
laboratories to address this issue, including sample
exchanges. The aim of these schemes has been to identify
and address issues with standardisation across multiple
platforms. They are now likely to form the basis of future
external quality assurance for clinical EV assays.
The large variability of EV levels detected even in
healthy individuals and the likelihood that levels will
overlap between health and disease makes it difficult to
establish clinical cut-offs for normal versus abnormal.
This can in part be rectified by using appropriate ROC
analysis to define the most appropriate cut-off within
a given population of patients. We must be aware that
this cut-off is likely to be significantly altered depend-
ing on the technology used to detect EVs and the
patient cohort being examined.
Interference from contaminating factors such as pla-
telets and lipids in plasma samples remains an issue for
EV analysis, both in research and clinical use. To mini-
mise these effects, we impose stringent processing and
storage requirements for plasma samples that we intend
to use for EV analysis. In the clinical setting, these strict
requirements may be impossible to achieve. Therefore,
we need to be mindful during assay development to
optimise assays for less-than-perfect samples and be
pragmatic in our approach to sample requirements, as
highlighted from the recent Clinical Wrap-Up session at
ISEV 2018 [54].
Finally, the generation of UoM statistics for EV assays
may be difficult to assess due to the pre-analytical vari-
ables known to impact detected EV levels. However,
UoM is an opportunity to provide a range of results in
which the true EV level falls. This is useful to both
researchers and clinicians, as it can indicate whether
a change in levels is significant or likely due to the
variability of the assay. Therefore, UoM calculation
should be encouraged for all EV analysis, even before it
reaches the clinical stage.
Conclusions
Although assay validation might not be considered the
most interesting or “sexy” side to EV research, it is
right to acknowledge its importance. Accreditation is
increasingly important for all clinical laboratories and
the standards required to achieve this accreditation are
becoming more and more stringent. Therefore, as we
move rapidly towards our goal of offering EV analysis
in diagnosis and monitoring of disease, we should
consider these parameters to ensure that we develop
the highest quality assays possible and ultimately the
best outcomes for patients.
All this said, it is proving to be possible, as Exosome
Diagnostics Inc, Waltham, USA who were recently the
Table 4. Challenges for clinical validation of EV diagnostics.
Challenges Solutions
Lack of International Reference
Preparation to determine
Trueness
Setting up and use of EQA schemes
Overlap between patients and
healthy controls
Setting an appropriate cut-off
using ROC analysis
Interference from lipaemic,
haemolytic and platelet
contaminated samples
Applying strict, but achievable
sample requirements for assays
Issues with sample stability Determining appropriate collection
and storage conditions that
minimise EV generation and
contaminating fractions of blood
components
Issues with sample diversity Stringent guidelines for sample
acceptance criteria
Establishing uncertainty of
measurement
Consideration of pre-analytical
variables to ensure accurate
reporting of EV levels
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first to release exosome-based diagnostics test have
achieved this for an EV Lung and prostate cancer diag-
nostic under its Clinical Laboratory Improvement
Amendments (CLIA) act of 1988 as qualified to perform
high complexity clinical testing and ISO 15189 certified
locations in USA and Germany [55]. Therefore, clini-
cally validated EV assays are achievable and this stan-
dard should be the goal for all new clinical techniques.
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